NCT04740801已完成不适用
Electrical Coupling Information From The RHYTHMIA HDx Mapping System and DIRECTSENSE Technology In The Treatment of Paroxysmal Atrial Fibrillation: A Non-Randomized Prospective Study With Contact Force
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 10
- 主要终点
- Association between Local Impedance drop values and PV reconnections
研究概览
简要总结
The objective of this study is to evaluate whether local impedance (DIRECTSENSE™) drop on the INTELLANAV STABLEPOINT™ ablation catheter is associated with late pulmonary vein (PV) reconnections and durable conduction block in patients undergoing de novo PV isolation (PVI) for treatment of paroxysmal atrial fibrillation (PAF).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •History of recurrent, symptomatic, paroxysmal atrial fibrillation (PAF), defined as atrial fibrillation (AF) that terminates spontaneously or with intervention (either procedure or drug therapy) within seven days of onset. Minimum documentation includes at least one AF episode electrocardiographically documented and at least one additional symptomatic recurrence with or without electrocardiographic documentation, within 365 days prior to enrollment.
- •Subjects who are eligible for an ablation procedure for paroxysmal AF according to international and local guidelines on catheter ablation of AF.
- •Subjects refractory or intolerant to at least one Beta Blocker, Calcium Channel Blocker, class I or III antiarrhythmic medication taken for the treatment of AF/AT (Atrial Tachycardia)/AFL (Atrial Flutter) or contraindicated to any class I or III antiarrhythmic medications, Beta Blocker or Calcium Channel Blocker.
- •Subjects who are willing and capable of providing informed consent.
- •Subjects who are willing and capable of participating in all testing associated with this clinical investigation at an approved clinical investigational center.
- •Subjects whose age is 18 years or above, or who are of legal age to give informed consent specific to local and national law.
排除标准
- •Any known contraindication to an AF ablation or anticoagulation
- •Continuous AF lasting longer than seven days from onset (no episodes within 365 days from enrollment)
- •History of previous LA ablation or surgical treatment for AF/AT/AFL
- •AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause
- •Subjects with life expectancy ≤ 6 months
- •Structural heart disease, heart conditions, or implanted devices as described below:
- •Left ventricular ejection fraction < 35% based on the most recent imaging (≤ 180 days prior to enrollment)*
- •LA diameter > 5.5 cm or LA volume >50 ml/m² indexed based on the most recent imaging (≤ 180 days prior to enrollment)*
- •Heart failure with New York Heart Association (NYHA) Class III or IV
- •Previous cardiac surgery (e.g. ventriculotomy or atriotomy, CABG, PTCA, stent procedure) within 90 days prior to enrollment
- •Implantable cardiac device procedures (e.g. PM, ICD, CRT) within 30 days prior to enrollment
- •Severe valvular disease or presence of a prosthetic - mechanical or biological - heart valve in the LA (not including valve repair and annular rings)
- •Severe mitral valve regurgitation or stenosis
- •Known or pre-existing severe pulmonary vein stenosis
- •Interatrial baffle, closure device, patch, or patent foramen ovale (PFO) occluder
- •Presence of LA appendage occlusion device
- •Presence of any pulmonary vein stents
- •Unstable angina or ongoing myocardial ischemia
- •Previous myocardial infarction within 90 days prior to enrollment
- •Vena cava embolic protection filter devices and/or known femoral thrombus;
- •Known left atrial thrombus, myxoma, or intracardiac mural thrombus
- •History of blood clotting or bleeding disease
- •Any prior history of documented cerebral infarct, TIA, or systemic embolism [excluding a post-operative deep vein thrombosis (DVT)] ≤180 days prior to enrollment
- •Active systemic infection
- •Pregnant, lactating (current or anticipated during study follow up), or women of childbearing potential who are, or plan to become, pregnant during the time of the study (method of assessment upon physician's discretion)
- •Subjects who are currently enrolled in any other concurrent study, with the exception of local mandatory governmental registries and observational studies/registries, without written approval from the sponsor
结局指标
主要结局
Association between Local Impedance drop values and PV reconnections
时间窗: 0-3 months
Correlation between local impedance drop collected during the blinded index procedure and sites of late PV reconnection/durable block at 3-months.
次要结局
- Association between Local Impedance drop values and acute PV reconnections(0-1 month)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
不适用
Bioelectrical Impedance Utilization and Dietary Intake Relation in the Breast Cancer Related LymphedemaBreast Cancer LymphedemasNCT03391206Severance Hospital228
进行中（未招募）
不适用
Contribution of the Evaluation of Body Composition by Connected Scale in the Effectiveness of a Reconditioning Program Through Physical Activity Adapted for Patients Suffering From Chronic DiseasesChronic DiseaseNCT06119594Assistance Publique - Hôpitaux de Paris90
已完成
不适用
Relationship Between LINQ™ Subcutaneous Impedance and Right-sided Hemodynamic MeasurementsHeart FailureNCT03608826Medtronic Cardiac Rhythm and Heart Failure12
已完成
不适用
Relation Between Bioelectrical Impedance Analysis (BIA) and CT-scan Analysis in the ICUMuscular AtrophyNCT02555670Amsterdam UMC, location VUmc222
已完成
不适用
Establishing Muscle Impedance Parameters With Electrical Impedance MyographyIBMInclusion Body MyositisNCT03633318Yale University31